Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wellness Wire Kansas.
Press releases published on April 8, 2025
The Center for Intentional Health Offers Cutting-Edge Cognitive Enhancement Program
EIN Presswire
·
April 8, 2025
The Center for Intentional Health expands its Cognitive Enhancement Program—an integrative, science-based solution to boost brain health, focus, and clarity. OVERLAND PARK, KS, UNITED STATES, April 8, 2025 /EINPresswire.com/ -- Cheryl L. Morgan, FNP, …
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
GlobeNewswire
·
April 8, 2025
LA JOLLA, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced enrollment of the …
Neuro RehabCare Announces Expanded Services for Brain Injury and Stroke Rehabilitation in Kansas City
EIN Presswire
·
April 8, 2025
SHAWNEE, KS, UNITED STATES, April 8, 2025 /EINPresswire.com/ -- Neuro RehabCare, a leading provider of neuro-rehabilitation services in Kansas City, is expanding its specialized Brain Injury Program and Stroke Rehabilitation Therapy. Located in Shawnee, …
Neuro RehabCare of Kansas City Is a Neurorehabilitation & Brain Injury Rehabilitation Center in Shawnee, KS
EIN Presswire
·
April 8, 2025
SHAWNEE, KS, UNITED STATES, April 8, 2025 /EINPresswire.com/ -- Neuro RehabCare of Kansas City proudly offers industry-leading neurorehabilitation at the brain injury rehabilitation center in Shawnee, Kansas. Committed to providing exceptional care and …
Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs
GlobeNewswire
·
April 8, 2025
WARREN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a healthcare company with dedicated efforts in immunotherapy and artificial intelligence, today announced that Mittul Mehta, Chief …
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease
GlobeNewswire
·
April 8, 2025
HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the closing of a $ …
National Minority Quality Forum Announces 2025 National Minority Health Month Theme: “Health Unlocked: Access, Alignment, Action”
GlobeNewswire
·
April 8, 2025
Washington, D.C., April 08, 2025 (GLOBE NEWSWIRE) -- The National Minority Quality Forum (NMQF) proudly announces the 2025 theme for National Minority Health Month: “Health Unlocked: Access, Alignment, Action.” This year’s theme recognizes the evolving …
Myriad Genetics Announces Inducement Awards
GlobeNewswire
·
April 8, 2025
SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, …
AMN Healthcare to Hold First Quarter 2025 Earnings Conference Call on Thursday, May 8, 2025
GlobeNewswire
·
April 8, 2025
DALLAS, April 08, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its first quarter 2025 financial results and second quarter 2025 outlook on Thursday, May 8, 2025, at 5:00 p.m. Eastern Time. …
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025
GlobeNewswire
·
April 8, 2025
PORTLAND, Maine, April 08, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
GlobeNewswire
·
April 8, 2025
SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases …
Clover Health to Report First Quarter 2025 Financial Results on May 6, 2025
GlobeNewswire
·
April 8, 2025
WILMINGTON, Del., April 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report first quarter 2025 financial results after market close on Tuesday, May 6 …
NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
GlobeNewswire
·
April 8, 2025
CALABASAS, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that …
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities
GlobeNewswire
·
April 8, 2025
SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings Inc., conducting business as QumulusAI …
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
GlobeNewswire
·
April 8, 2025
Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease Education Campaign for Healthcare Providers called Move GBS Forward …
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
GlobeNewswire
·
April 8, 2025
NX-5948 assigned the nonproprietary name “bexobrutideg” U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemia Achieved $7M in milestones and a $15M license extension fee from ongoing collaboration with …
BON Announces Unlocking Broccoli's Nutritional Power: Advanced Delivery System for Glucoraphanin Activation
GlobeNewswire
·
April 8, 2025
XI’AN, China, April 08, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced our biotech innovation addresses …
Major Medicaid and ACA Marketplace changes could be coming: What consumers need to know now
GlobeNewswire
·
April 8, 2025
Minneapolis, MN, April 08, 2025 (GLOBE NEWSWIRE) -- Millions of people who rely on Medicaid and ACA Marketplace coverage (Obamacare) could be impacted by sweeping federal policy changes under consideration. Healthinsurance.org is closely tracking these …
Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference
GlobeNewswire
·
April 8, 2025
DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference. The Company …
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
GlobeNewswire
·
April 8, 2025
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive …